D. Harrington

发表

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

R. Fonseca, M. Oken, R. Kyle, 2002, Blood.

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Kenneth C. Anderson, Benjamin Djulbegovic, Bart Barlogie, 2003, British journal of haematology.

Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy

R. Fonseca, B. Ness, D. Harrington, 2001, Leukemia.

Representativeness of Participants in the Cancer Care Outcomes Research and Surveillance Consortium Relative to the Surveillance, Epidemiology, and End Results Program

K. Kahn, A. Zaslavsky, P. Catalano, 2013, Medical care.

Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis

E. Emanuel, S. George, S. Joffe, 2004, BMJ : British Medical Journal.

The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer

L. Waldron, G. Parmigiani, John Quackenbush, 2019, Cancer Epidemiology, Biomarkers & Prevention.

The impact of stroma on the discovery of molecular subtypes and prognostic gene signatures in serous ovarian cancer

L. Waldron, G. Parmigiani, John Quackenbush, 2018 .

Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium.

K. Kahn, R. Fletcher, D. West, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage ii aggressive histologic type non‐hodgkin's lymphoma

J. Earle, J. Glick, M. O’connell, 1988, Cancer.

The effect of intensive intermittent maintenance therapy in advanced low‐grade non‐Hodgkin's lymphoma

M. O’connell, O. Kucuk, D. Harrington, 1987, Cancer.

Statistical and empirical evaluation of histopathologic reviews for quality assurance in the eastern cooperative oncology group

D. Harrington, K. Gilchrist, R. Neiman, 1988, Cancer.

Pentostatin induces durable remissions in hairy cell leukemia.

M. O’connell, J. Bennett, D. Harrington, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group.

M. O’connell, J. Bennett, D. Harrington, 1990, Haematology and blood transfusion.

Phase II clinical trial of carboplatin in relapsed and refractory leukemia.

M. Oken, J. Bennett, D. Harrington, 1992, Leukemia.

Escalating the intensity of postremission therapy improves the outcome in acute myeloid leukemia: The ECOG experience

M. O’connell, J. Bennett, D. Harrington, 1992 .

Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.

M. O’connell, J. Bennett, D. Harrington, 1992, Leukemia.

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.

F. Appelbaum, C. Willman, J. Bennett, 1998, The New England journal of medicine.

Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin).

M. O’connell, J. Bennett, D. Harrington, 1987, The New England journal of medicine.

Heart and Lung Transplants from HCV‐Infected Donors to Uninfected Recipients

P. Camp, D. Harrington, M. Mehra, 2019, The New England journal of medicine.

Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma.

A. Qureshi, A. Jambusaria-Pahlajani, C. Schmults, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

M. Rue, R. Fonseca, M. Oken, 2003, Blood.

Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia.

M. Oken, M. O’connell, J. Bennett, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients' experiences with care for lung cancer and colorectal cancer: findings from the Cancer Care Outcomes Research and Surveillance Consortium.

K. Kahn, A. Zaslavsky, P. Ganz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma

M. Oken, J. Glick, R. Kyle, 1997, Cancer.

Cooperative Oncology Group Study 13) in Multiple Myeloma : An Eastern Δ 13 Abnormalities ( Hybridization Detection of Chromosome in Situ Fluorescence and Prognostic Significance of Interphase

R. Fonseca, M. Oken, D. Harrington, 2013 .

Prognostic correlation of HLA‐DR expression in large cell lymphoma as determined by LN3 antibody staining. An eastern cooperative oncology group (ECOG) study

D. Harrington, R. Neiman, C. Mack, 1990, Cancer.

Understanding cancer patients’ experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey

K. Kahn, A. Zaslavsky, P. Catalano, 2006, Supportive Care in Cancer.

A comparison between the Rappaport Classification and Working Formulation in cooperative group trials: the ECOG experience.

D. Harrington, R. Neiman, R. Mann, 1992, Hematologic pathology.

Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.

Robert H Fletcher, Katherine L Kahn, Deborah Schrag, 2010, JAMA.

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.

K. Kahn, J. Pendergast, R. Fletcher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient perspectives on breast cancer treatment plan and summary documents in community oncology care

Anne Moore, J. Griggs, R. Theriault, 2013, Cancer.

Bayesian cure rate models for malignant melanoma: a case‐study of Eastern Cooperative Oncology Group trial E1690

Joseph G. Ibrahim, Ming-Hui Chen, David P. Harrington, 2002 .

Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.

D. Weisenburger, J. Armitage, P. Bierman, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial.

B. C. Donovan, J. Polak, M. Bettmann, 1990, Radiology.

Varying intensity of postremission therapy in acute myeloid leukemia.

M. Oken, M. O’connell, J. Bennett, 1992, Blood.

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.

L. Gordon, J. Glick, M. O’connell, 1992, The New England journal of medicine.

Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.

K. Kahn, R. Fletcher, P. Ganz, 2010, JAMA.

Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease

D. Zahrieh, D. Harrington, Stephanie J. Lee, 2006 .

The Aftermath of Falsified Data in Breast Cancer Trials

D. Harrington, 1997 .